

Special Issue

FAP-Ligands and Its Clinical Translation in Cancers

Message from the Guest Editors

In this special issue, we are focusing on the new target with the scope of tumor micro-environment and its pathogenesis using radioligands in the field of nuclear medicine. Within the last years, FAP-ligands has been proven to play an important role for cancer detection, but also in pathological conditions beyond oncology, FAP-ligands might also serve as additional important imaging surrogates in chronic inflammatory changes or even cardio-vascular diseases. Due to this exciting evolution of using FAP-ligand in the field of nuclear medicine, we would like to invite academic researchers and scientist to submit recent research results of FAP-ligands in diagnostic but also theranostic investigations.

Nuclear medicine has been tremendously changed by the introduction of new ligands such as PSMA in conjunction with prostate cancer. Recently, novel innovative ligands beyond one tumor entity have emerged. Particular, new FAP-ligands targeting tumor microenvironment (cancer associated fibroblasts) seem to be a highly promising evolution in the field of molecular imaging and therapy for its whole-cancer targeting.

Guest Editors

Prof. Dr. Frederik L. Giesel

Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany

Dr. Tadashi Watabe

Osaka University Graduate School of Medicine, Suita, Japan

Deadline for manuscript submissions

closed (31 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/116183

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)